Revisiting comorbidities in gout: A cluster analysis

Annals of the Rheumatic Diseases

Volumn 74, Issue 1, 2015, Pages 142-147

  Richette, Pascal ^a   Clerson, Pierre ^b   Périssin, Laure ^c   Flipo, René Marc ^d   Bardin, Thomas ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Orgamétrie Biostatistiques   (France)

^c Laboratoires Menarini France   (France)

^d UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

ABDOMINAL CIRCUMFERENCE; ADULT; AGED; ANGINA PECTORIS; ARTICLE; BODY MASS; CLUSTER ANALYSIS; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE DURATION; DYSLIPIDEMIA; FATTY LIVER; FEMALE; FRANCE; GLOMERULUS FILTRATION RATE; GOUT; HEART FAILURE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NEOPLASM; OBESITY; PHENOTYPE; PREVALENCE; SEX DIFFERENCE; WAIST CIRCUMFERENCE; CORONARY DISEASE; DYSLIPIDEMIAS; LIVER DISEASES; MIDDLE AGED; NEOPLASMS; RENAL INSUFFICIENCY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CLUSTER ANALYSIS; COHORT STUDIES; COMORBIDITY; CORONARY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; FRANCE; GOUT; HEART FAILURE; HUMANS; HYPERTENSION; LIVER DISEASES; MALE; MIDDLE AGED; NEOPLASMS; OBESITY; PREVALENCE; RENAL INSUFFICIENCY;

EID: 84918589627     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203779     Document Type: Article

References (25)

1. Reginato AM, Mount DB, Yang I, et al. The genetics of hyperuricaemia and gout. Nat Rev Rheumatol 2012;8:610-21.
2. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther 2010;12:223.
3. Stamp LK, Chapman PT. Gout and its comorbidities: implications for therapy. Rheumatology (Oxford) 2013;52:34-44.
4. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med 2012;125:679-87.
5. Perez-Ruiz F, Martinez-Indart L, Carmona L, et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis 2014;73:177-82.
6. Krishnan E, Pandya BJ, Lingala B, et al. Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction. Arthritis Res Ther 2012;14:R10.
7. Krishnan E, Svendsen K, Neaton JD, et al. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008;168:1104-10.
8. Dalbeth N, So A. Hyperuricaemia and gout: state of the art and future perspectives. Ann Rheum Dis 2010;69:1738-43.
9. Richette P, Bardin T. Gout. Lancet 2010;375:318-28.
10. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008;359:1811-21.
11. Mooi E, Sarstedt M. Cluster analysis. In: A concise guide to market resarch. Berlin: Springer, 2011:237-84.
12. Afzali A, Weiss NS, Boyko EJ, et al. Associatio between serum uric acid level and chronic liver disease in the United States. Hepatology 2010;52:578-89.
13. Robinson PC, Merriman TR, Herbison P, et al. Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999-2009. Rheumatology (Oxford) 2013;52:118-26.
14. Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008;67:960-6.
15. Primatesta P, Plana E, Rothenbacher D. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskelet Disord 2011;12:103.
16. Wu EQ, Forsythe A, Guerin A, et al. Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy. Am J Ther 2012;19:e157-66.
17. Liote F, Lancrenon S, Lanz S, et al. GOSPEL: prospective survey of gout in France. Part I: design and patient characteristics (n=1003). Joint Bone Spine 2012;79:464-70.
18. Doherty M, Jansen TL, Nuki G, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis 2012;71:1765-70.
19. Mahr A, Katsahian S, Varet H, et al. Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Ann Rheum Dis 2012;72:1003-10.
20. Choi HK, Atkinson K, Karlson EW, et al. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005;165:742-8.
21. De Marco MA, Maynard JW, Huizinga MM, et al. Obesity and younger age at gout onset in a community-based cohort. Arthritis Care Res (Hoboken) 2011;63:1108-14.
22. Chen JH, Pan WH, Hsu CC, et al. Impact of obesity and hypertriglyceridemia on gout development with or without hyperuricemia: a prospective study. Arthritis Care Res (Hoboken) 2013;65:133-40.
23. Xu C, Yu C, Xu L, et al. High serum uric acid increases the risk for nonalcoholic Fatty liver disease: a prospective observational study. PLoS ONE 2010;5:e11578.
24. Joosten LA, Netea MG, Mylona E, et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1beta production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum 2010;62:3237-48.
25. Puig JG, Michan AD, Jimenez ML, et al. Female gout. Clinical spectrum and uric acid metabolism. Arch Intern Med 1991;151:726-32.